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Abstract 
Leishmaniasis comprises a group of diseases caused by protozoa of the genus Leishmania 
that are transmitted via the bite of female phlebotomine sand-flies. Infections may be cutaneous 
or visceral depending on the species, however, visceral leishmaniasis (VL) is significantly more 
deadly than cutaneous leishmaniasis (CL). Leishmaniasis is present in nearly 100 countries with 
approximately 200,000 to 500,000 new cases annually for visceral infections, about 50,000 of 
which are fatal. VL has a mortality rate of roughly 75 to 95% given no treatment and 5 to 10% 
with standard treatment pentavalent antimonials (SbV) such as sodium stibogluconate (SSG) 
which are toxic and require prolonged intra-peritoneal or intravenous administration leading to 
incomplete treatment regimes. Furthermore, the widespread use of antimonials has led to a 
rampant increase in the prevalence of drug resistant parasites. Ibrutinib is an anticancer drug 
which has been shown to modify immune cell responses and has previously shown effectiveness 
against CL. In this study, we sought to evaluate oral treatment with ibrutinib as a host-directed 
therapy for VL caused by Leishmania donovani using mouse models of infection. 
Oral ibrutinib treatment resulted in significantly reduced liver and spleen parasite burden 
as compared to SSG and vehicle solution controls with greater numbers of mature liver 
granulomas. Ibrutinib-treated mice had a reduced influx of Ly6Chi inflammatory monocytes, 
known to cause susceptibility to L. donovani and treatment was also associated with the release 
of protective cytokines in the liver and spleen: IFN-γ, tumor necrosis factor α, IL-4, and IL-13. 
No changes were noted in B cell populations or IgG levels indicative of a B cell independent 
mechanism. Our results demonstrate oral ibrutinib is substantially more effective than SSG (70 
mg/kg) in reducing parasite burden L. donovani and acts through alteration of host immunity, 
therefore, ibrutinib has potential as an immunomodulatory treatment for VL. 
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Leishmaniasis is a collective term for pathological conditions caused by Leishmania 
parasite infection and represents a large healthcare burden in many developing countries. 
Leishmania are obligate intracellular protozoans that may infect the skin, mucosal membranes or 
visceral organs. Leishmaniasis is a neglected tropical disease as classified by the World Health 
Organization, with over 12 million individuals currently infected globally and 2 million new 
annual cases (WHO 2018). Leishmania is present in over 80 tropical and subtropical countries 
and there are at least 20 distinct Leishmania species. Leishmaniasis may be transmitted by over 
90 known sand-fly species and more than 70 different animals including humans are potential 
Leishmania reservoirs (WHO 2018, CDC 2013). During a blood feeding, motile Leishmania 
promastigotes are transferred from the sand-fly into a human or animal host where they are 
phagocytized by neutrophils, macrophages, or dendritic cells (DCs); Leishmania parasites 
differentiate into amastigotes and replicate within phagolysosomes, eventually rupturing the host 
cell and releasing the parasites. The extracellular amastigotes are again phagocytized by 
neutrophils, macrophages, DCs or may be taken in by a feeding sand-fly and the infection cycle 
continues (CDC 2013). 
 Cutaneous leishmaniasis (CL) is the most prevalent form with an estimated 700,000 – 2 
million cases a year, however, VL is the most dangerous type of Leishmania infection, surpassed 
only by malaria in annual fatalities (WHO 2018, CDC 2013, The Center for Food Security and 
Public Health Factsheets 2017). The primary consequence of cutaneous infections is disfiguring 
scarring at the lesion sites however VL has a mortality rate of 75 to 95% without proper 




McGwire and Satoskar 2014). Infection with Leishmania donovani or Leishmania chagasi is the 
cause of VL and parasites are dispersed through the blood to the bone marrow, spleen, and liver 
(de Freitas et al. 2016). Patients with visceral infections develop conditions such as fever, 
anemia, and hepato-splenomegaly (swelling of spleen and liver) which become chronic and 
eventually cause death (WHO 2018, McGwire and Satoskar 2014). Up to 20% of VL patients 
also experience reoccurring infections following successful treatment with SSG which may 
manifest symptoms in the form of large diffuse parasite-laden skin pustules known as post kala-
azar dermal leishmaniasis (Okwor and Uzonna 2016, Zijlstra et al. 2017). 
 The pentavalent antimonial drug sodium stibogluconate (SSG) was introduced 
approximately 100 years ago and remains the preferred treatment for all forms of leishmaniasis 
worldwide despite cardiac, renal, and hepatotoxicity with required daily parenteral injections for 
at least 20 days (de Freitas et al. 2016). Since Leishmania infections commonly occur in remote 
impoverished areas, treatment may be abruptly discontinued due to cost or supply issues which 
promotes the selection and expansion of resistant parasite populations. The prolonged and often 
inappropriate use of antimonial compounds has increased the prevalence of drug-resistant 
parasites worldwide, particularly L. donovani (Sundar et al. 2000, Lira et al. 1999, Clementi et al. 
2011, Polonio and Efferth 2008). Other effective medications such as amphotericin B and 
miltefosine have developed the same problem of promoting the evolution of parasite resistance 
as both drugs work by targeting parasitic components directly in addition to being less accessible 
in endemic areas and possessing similar, albeit milder, side effects as SSG (Rai et al. 2013, Rijal 
et al. 2013, Burza et al. 2014, Sinha et al. 2010, Sunyoto et al. 2018). There is a pressing need to 
explore new treatment options for VL and therapies that modulate host immune systems are an 




Ibrutinib is a potent orally bio-available small molecule irreversible inhibitor of Bruton’s 
tyrosine kinase (BTK) and interleukin-2 inducible kinase (ITK) and is approved by the FDA for 
the treatment of chronic lymphocytic leukemia and mantle cell lymphoma as well as other B cell 
malignancies (Wang et al. 2015, Wu et al. 2016). BTK and ITK belong to the TEC-family 
tyrosine kinases which are essential for intracellular signaling of both B and T lymphocytes 
respectively in humans (Wang et al. 2015, Wu et al. 2016, Gomez-Rodriguez et al. 2011). BTK 
is critical to B cell receptor signaling, mediating B cell proliferation which promotes the 
pathogenesis of leishmaniasis (Arcanio et al. 2017, Silva-Barrios et al. 2016). ITK is present 
within T cells and participates in proliferation, differentiation as well as the development of 
specific T helper cell subsets (Gomez-Rodriguez et al. 201, Kosaka et al. 2006). The balance of 
different helper T cell populations can have drastic effects on Leishmania parasite pathogenesis. 
Previous studies from our lab have shown that ibrutinib mediated ITK inhibition causes 
suppression of T helper type 2 (Th2) T cell differentiation in favor of T helper type 1 (Th1), 
preventing disease progression L. major induced CL in a mouse model (Dubovsky et al. 2013). 
Overall, these results suggest that ibrutinib may have potential use as a host targeted therapy to 
suppress immune response which has been associated with negative outcomes in visceral 
Leishmania infections, namely, B cell proliferation and Th2 differentiation.  
Here we determined the effectuality of ibrutinib for experimental L. donovani infection in 
a mouse model. We demonstrate that oral ibrutinib treatment is significantly more effective 
against L. donovani than conventional SSG. Furthermore, our studies show that ibrutinib 






6–7-week-old female wild-type BALB/c mice were infected by IV injection of 107- L. 
donovani amastigotes taken from infected hamster spleens. Two weeks after infection, the mice 
were randomized into four groups of five mice: two groups treated with 6mg/kg Ibrutinib 
dissolved in the vehicle or vehicle alone (0.5% methyl cellulose + 0.1% SDS/SLS) daily via oral 
gavage for 2 weeks or and two groups treated with one dose of 70mg/kg sodium stibogluconate 
(SSG) or PBS given as an intraperitoneal (IP) injection. On day 14 post-treatment, (two weeks 
following infection) Leishman-Donovan Units were used to quantify parasite burden by staining 
tissue sections with Giemsa stain and counting parasites per nucleated cell then multiplying by 
organ weight (mg). 
Analysis of Histopathology 
 Thin sections of livers taken from infected mice were fixed in formalin, stained with 
hematoxylin-eosin, and assessed for granuloma formation by a certified pathologist as one of the 
following: no response, developing granuloma, mature granuloma, granuloma cleared of 
parasites and tissue cleared of granulomas. Granuloma totals were taken as average of the 5 mice 
from each group. 
Cytokine Assessment by Enzyme-Linked Immunosorbent Assay (ELISA) and Greiss Assay 
 Spleen cells were isolated from infected spleens into RPMI 1640 medium supplemented 
with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% HEPES. The cells were 
centrifuged, blood cells were lysed using ACK lysis buffer, and remaining viable cells were 
counted using trypan blue exclusion. 5 × 105 splenocytes/well in RPMI 1640 medium were 




three days. The supernatants were collected to assess the levels of the cytokines, interferon γ 
(IFN-γ), tumor necrosis factor α (TNF-α), interleukin 4 (IL-4), interleukin 10 (IL-10), interleukin 
12 (IL-12), and interleukin 13 (IL-13). Supernantant nitric oxide (NO) levels were assessed using 
the Greiss assay. 
Reverse Transcription–Polymerase Chain Reaction (RT-PCR) Analysis 
 TRIzol extraction (Life Technologies, Carlsbad, CA) was used to isolate RNA from 
livers and spleens. Complementary DNAs were prepared with an iScript reverse transcription kit, 
and RT-PCR was done in a CFX 96 RT-PCR cycler using IQ SYBR green super mix (Bio-Rad, 
Hercules, CA). The primers were selected using the Harvard primer database 
(http://pga.mgh.harvard.edu/primerbank). Data was normalized by using the housekeeping gene 
β-actin and presented as fold induction over uninfected mouse gene expression. 
Flow Cytometry 
 To determine the effect of ibrutinib on populations of immune cells in infected organs, a 
Percoll density gradient with centrifugation was used to isolate the splenocytes and immune 
cells. 1 × 106 cells were incubated with mouse serum to prevent non-specific binding then 
stained with fluorescent antibodies for the proteins: CD3, CD4, CD8, Tim3, ST2, DX5, CD19, 
IFN-γ, IL-4, CD11b, Ly6G, Ly6C, and F4/80 (Biolegend, San Diego). Cells were analyzed using 








 Unpaired student t tests were utilized to determine if differences between experimental 




Oral Ibrutinib Treatment Is Effective for L donovani Infection 
To evaluate if ibrutinib treatment is effective for VL, we examined the liver and spleen 
parasite burdens of mice infected with L. donovani that were treated with ibrutinib, vehicle, SSG, 
and PBS. Mice that were treated with ibrutinib had reduced parasite numbers in the liver and 
spleen compared to controls and SSG, there was approximately a 50% increased reduction of 
parasites in the liver and and a 75% increased reduction in the spleen as compared to controls 
(Figure 1). Together, our results show that oral ibrutinib treatment is an effective therapy for VL 




Figure 1. Treatment with Ibrutinib Reduces Parasite Burden 
 
A, Study timeline. 6-7-week-old female BALB/C mice were infected with L. 
donovani amastigotes. Two weeks following infection, the mice were randomized into 4 groups 
of 5 mice with assigned treatments. Mice in the two different oral treatment groups received 
ibrutinib (6 mg/kg) or vehicle formulations every day for two weeks while the other groups 
recieved a single IP injection of 70 mg/kg SSG and PBS. Two weeks after infection, livers and 
spleens were harvested and parasitic load was assessed. The quantification of parasite load was 
performed using Leishman-Donovan units (LDU) ± standard error of mean value. *P < .05 and 






Granuloma Maturation in the Liver 
Final parasite clearance in the liver is mediated by mature granulomas and therefore 
hepatic granuloma formation is a critical step to relapse-free recovery from VL (Murray 2000, 
Murray 2001). Evaluation of liver sections showed that ibrutinib treated mice had significantly 
more mature granulomas than vehicle and SSG treated controls with no statistical difference in 
the number of developing granulomas (Figure 2).  
Figure 2. Treatment with Ibrutinib Improves Maturation of Liver Granulomas 
 
Livers were harvested from each of the treatment groups and assessed for granuloma formation 
using sections of tissue stained with hematoxylin-eosin. A, Representative images of liver 




by certified pathologist. The number of granulomas was assessed per 10 high-power fields at 
200× magnification and are indicated as mean ± standard error of the mean **P < .01, using 
unpaired t test. 
Treatment with Ibrutinib Increases Protective Cytokine Expression in Livers and Spleens 
 To discern a potential mechanism of antileishmanial activity caused by ibrutinib 
treatment, we compared the livers and spleen cytokine profiles of mice infected with L. 
donovani. Ibrutinib-treated mice had increased Ifng and Tnfa messenger RNA (mRNA) 
expression in the liver when compared with mice treated with vehicle alone (Figure 3). Elevated 
expression of Il4, Il13, and Stat6 mRNA, was also observed in the spleens and livers of mice 
treated with ibrutinib (Figure 3). No difference in Nos2 or Stat1 mRNA expression were noted 
(Figure 3).  






Treatment with ibrutinib treatment invokes simultaneous Th1 and Th2 immune responses during 
L. donovani infection. Liver and spleen gene expression was analyzed using rtPCR. Levels of 
mRNA in the liver and spleen that encode the following factors were assessed: interferon γ 
(Ifng; A), tumor necrosis factor α (Tnfa; B), Nos2 (Nos2; C), STAT1 (Stat1; D), interleukin 4 
(Il4; E), interleukin 13 (Il13; F), arginase 1 (Arg1; G), and STAT6 (Stat6; H). Data is represented 
as fold expression over values obtained from non-infected wild type mice. *P < .05 and 
**P < .01, using unpaired t test. 
 
Increased Expression of IL-4 and IL-13 by Antigen Stimulated Splenocytes 
 To correlate increased levels of Il4 and Il13 mRNA in the spleen with increased levels of 
the corresponding cytokines, splenocytes isolated from vehicle and ibrutinib treated mice were 
stimulated with L. donovani antigen for three days, and levels of IL-4 and IL-13 in the culture 
supernatants were assessed using ELISA. Coinciding with Il4 and Il13 mRNA expression, 
splenocytes isolated from mice treated with ibrutinib secreted increased amounts of IL-4 and IL-
13 into the supernatant (Figure 4). Decreased IFN-γ was observed in the supernatant of the 
splenocytes of ibrutinib treated mice as opposed to treatment with vehicle which was unexpected 
based on previous studies. No significant differences were observed for IL-10, TNF-α, and NO 




Figure 4. Increased Expression of Protective Cytokines by Antigen Stimulated Spleen Cells
 
A, B, C, D, E, Splenocytes were harvested and isolated into single-cell suspensions which were 
re-stimulated with L. donovani antigen for three days to assess secretion of cytokines into culture 
supernatants using ELISA. F, A Griess assay was performed to assess NO production by 
splenocytes. Data is represented as the mean ± standard error of the mean *P < .05 and 
**P < .01, using unpaired t test. 
Ibrutinib Treatment Reduced Accumulation of Ly6Chi Inflammatory Monocytes 
 Recent work done in our lab demonstrates that Ly6Chi inflammatory mediate 
pathogenesis in VL, as they are preferentially targeted by L. donovani during infection (Terrazas 
et al. 2017). As it was also previously observed that ibrutinib alters characteristics of other 
myeloid lineage derived cells such as macrophages and neutrophils, we utilized flow cytometry 
to assess populations of Ly6Chi inflammatory monocytes in the livers and spleens of mice treated 




Ly6Chi inflammatory monocytes in the livers and spleens when compared with controls (Figure 
5A and 5B).  
Figure 5. Reduced Influx of Ly6Chi Inflammatory Monocytes
 
Treatment with ibrutinib potentially effects many cell populations associated with VL disease 
progression. Here, myeloid cell populations in the liver and spleen were analyzed utilizing flow 
cytometry. A, Dot plots representing different myeloid cell populations from vehicle and 
ibrutinib treated mice livers and spleens. P1 shows the inflammatory monocyte population 
(CD11b+Ly6ChighLY6G−), P2 shows macrophages (CD11b+Ly6Clow LY6G−), and P3 shows 
neutrophils (CD11b+Ly6C−LY6G+). B, Number of Ly6Chi cells after gating for CD11b in the 






The results of this study show that ibrutinib is an effective treatment for VL caused by L. 
donovani and has greater efficacy than traditional SSG therapy in reducing liver / spleen parasitic 
burden. Treatment with ibrutinib improved mature granuloma formation in the liver, increased 
protective cytokine production, along with a reduced influx of Ly6Chi inflammatory monocytes 
known to exacerbate the disease. These observations demonstrate that ibrutinib has potential to 
be a novel host-directed therapy for VL. 
 All current therapeutic options for leishmaniasis use drugs which act through direct 
cytotoxicity to the parasites and administration of these treatments is toxic to the host and often 
prolonged, resulting in lack of adequate compliance from patients. The evolution of drug-
resistant parasite populations is a growing problem promoting the global spread of VL and 
insights on the mechanisms of host immune response -pathogen interactions can lead to 
development of treatments for Leishmania infection which target the host. Treatments which 
target host pathways required for survival of parasites or promote host immunity to improve 
destruction and clearance of parasites may be an effective solution to the increasing threat of 
parasite resistance. Recent studies done by our group have found that Leishmania mexicana entry 
into phagocytic host cells is mediated by PI3Kγ and inhibition of this enzyme impairs CL 
progression, additionally, blockage of CCR2 to reduce numbers of Ly6Chi inflammatory 
monocytes in L. donovani infected mice causes significant parasite burden reductions in the 
viscera (Cummings et al. 2012) (Terrazas et al. 2017). In this current study, ibrutinib was shown 
to be substantially more efficacious than the conventional antileishmanial drug SSG for treating 




burden when compared with SSG, vehicle, and PBS groups. Additionally, ibrutinib treatment 
was associated with enhanced production in the liver of both Th1 and Th2 associated mRNA 
transcripts, along with improved capability of splenocytes stimulated with L. donovani antigen to 
produce IL-4 and IL-13 compared to vehicle controls. 
 The results of this study show that mice infected with L. donovani which receive ibrutinib 
treatment produce increased levels of the Th2 associated cytokines IL4 and IL13 which contrasts 
with our studies of L. major induced CL where ibrutinib treatment resulted in decreased levels of 
these cytokines in lymph nodes (Dubovsky et al. 2013). The mechanisms of ibrutinib treatment 
that induce the profound variety of cytokine responses in CL as opposed to VL remain undefined 
however these differences could be attributed in part to varying organ specific effects of 
ibrutinib. It has been demonstrated that IL-4 and IL-13 promote susceptibility to CL caused by L. 
major and L. mexicana however it also appears that these particular cytokines are essential to 
resolve VL, develop mature granulomas in the liver, and promote effective immune responses to 
particular chemotherapies (Hurdayal and Brombacher 2014, Kopf et al. 1996, Gupta et al. 2013, 
Satoskar et al. 1995, Stäger et al. 2003, McFarlane et al. 2011, Alexander et al. 2000, Murray et 
al. 2005). Consistent with these previous studies, livers that were taken from infected ibrutinib 
treated mice had significantly more mature granulomas than control groups. Our results show 
that ibrutinib mediated antileishmanial actions in experimental VL are caused by the promotion 
of protective cytokine release and suppression of immune-cell responses which increase 
susceptibility to the disease. 
 Several experimental and clinical studies have demonstrated that B cell proliferation and 




hypergammaglobulinemia from activation of polyclonal B cells which is correlated with disease 
exacerbation, additionally, B cells secrete IL-10 which has been shown to promote susceptibility 
to VL (Smelt et al. 2000, Gardinassi et al. 2014, Deak et al. 2010). Given ibrutinib’s ability to 
block B cell receptor activation through the inhibition of BTK, we examined the effect of 
ibrutinib treatment on B cell populations. Contrary to the expected result, analysis of 
immunoglobulin G levels in the serum as well as populations of B cells in the spleen found there 
were no significant differences between groups. The results of these analysis suggest the ability 
of ibrutinib to promote parasite clearance was not due to B cell suppression. 
 The prototypical host cells of Leishmania parasites are phagocytic myeloid cells such as 
monocytes and macrophages, and recent studies from our lab demonstrated that L. donovani 
preferentially targets Ly6Chi inflammatory monocytes which begin to accumulate in the viscera 
during infection (Terrazas et al. 2017). The data from this study shows that ibrutinib treated mice 
livers and spleens have a significant reduction in Ly6Chi inflammatory monocyte influx. Currently it 
is not clear how simultaneous ITK/BTK inhibition caused reductions in the accumulation of 
inflammatory monocytes, however, in-progress studies occurring in our lab have shown that ibrutinib 
induces differentiation of Ly6Chi inflammatory monocytes into DCs. Regardless of the mechanism, a 
reduction of Ly6Chi inflammatory monocytes is a least in part responsible for parasite clearance from 
infected organs of mice treated with ibrutinib. 
 In conclusion, this data shows that ibrutinib treatment is safer and more effective than 
traditional SSG treatment and demonstrates that anti-parasitic action is mediated by the 
promotion of a protective immune response. Due to its overall efficaciousness and negligible 
toxicity, ibrutinib has potential as a novel host immunomodulatory treatment for VL caused by 
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